NUVB

Nuvation Bio Inc.

1.77 USD
-0.01 (-0.56%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Nuvation Bio Inc. stock is up 6.63% since 30 days ago. The next earnings date is Mar 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 February’s closed higher than January.

About Nuvation Bio Inc.

Nuvation Bio Inc. focuses on the development of therapeutic candidates for oncology. Lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. Company was formerly known as RePharmation Inc.